Phentermine, a diminutive molecular compound, acts as an agonist that targets the TAAR1 receptor, which boasts a primary function as an appetite suppressant that caters to the management of obesity. UCB originally developed this drug, and it was given the nod for approval on the 4th of May 1959. Phentermine unleashes a binding process whereby the TAAR1 receptor in the hypothalamus is singled out, thereby creating a surge of neurotransmitter release. Consequently, norepinephrine and dopamine are boosted, thus facilitating the reduction of hunger and fostering weight loss. This medication is typically prescribed for a short period, to be used alongside a calorie-restricted diet and exercise, to encourage weight loss in obese individuals. However, one must remain vigilant of potential side effects, which may include dry mouth, insomnia, and an escalated heart rate. It is crucial to emphasize the necessity of adhering to expert medical counsel when using this drug, as it is not a long-term solution for obesity management, but can certainly prove efficacious when utilized judiciously. Click on the image below to begin the exploration journey of Phentermine through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!